Success Metrics

Clinical Success Rate

66.7%

Based on 2 completed trials

Completion Rate

67%(2/3)

Active Trials

3(33%)

Results Posted

0%(0 trials)

Terminated

1(11%)

Phase Distribution

Ph phase_1

22%

Ph phase_2

33%

Ph not_applicable

11%

Ph phase_3

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution9 total trials

Phase 1Safety & dosage

2(22.2%)

Phase 2Efficacy & side effects

3(33.3%)

Phase 3Large-scale testing

3(33.3%)

N/ANon-phased studies

1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(2)

Terminated(1)

Other(3)

Detailed Status

unknown3

Recruiting3

Completed2

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 3

Trials by Phase

Phase 12 (22.2%)

Phase 23 (33.3%)

Phase 33 (33.3%)

N/A1 (11.1%)

Trials by Status

completed222%

unknown333%

recruiting333%

terminated111%

Recent Activity

3 active trials

Showing 5 of 9

recruitingnot_applicable

Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma

NCT06893887

recruitingphase_2

Icaritin in Combination With AG in Patients With Previously Untreated Advanced Pancreatic Ductal Adenocarcinoma

NCT06825546

recruitingphase_3

Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)

NCT05594927

unknownphase_2

Tace With Icaritin in First-line Treatment of Middle and Advanced HCC in Child Grade B Patients

NCT06285149

terminatedphase_3

The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects

NCT03236649

View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials

NCT06893887Not Applicable

Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma

Recruiting

NCT06825546Phase 2

Icaritin in Combination With AG in Patients With Previously Untreated Advanced Pancreatic Ductal Adenocarcinoma

Recruiting

NCT05594927Phase 3

Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)

Recruiting

NCT06285149Phase 2

Tace With Icaritin in First-line Treatment of Middle and Advanced HCC in Child Grade B Patients

Unknown

NCT03236649Phase 3

The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects

Terminated

NCT01972672Phase 2

The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma

Completed

NCT03236636Phase 3

The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects

Unknown

NCT02496949Phase 1

A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors

Completed

NCT01278810Phase 1

Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients

Unknown

All 9 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 9